Today, the Leukemia & Lymphoma Society (LLS) made an exciting announcement regarding a new therapy for patients with acute myeloid leukemia (AML), the same disease that Erin suffered from.

“Progress in treating AML, one of the most deadly blood cancers, took an important step forward today with the U.S. Food and Drug Administration (FDA) approval of ivosidenib for patients who have a specific genetic mutation called IDH1.

The approval of this oral, targeted therapy provides a critical new option for AML patients with this particular subtype who have relapsed or did not respond to prior treatment. The IDH1 genetic marker is found in approximately six to 10 percent of the 20,000 people in the U.S. diagnosed with AML each year.

Ivosidenib is the sixth AML therapy approved by the FDA in the past two years, continuing much needed progress for patients who desperately need new treatment options. As a leader in the offensive against AML, LLS played a significant role in helping to advance all of these approved therapies.”